Datroway: Dosage Form, Projected Sales, NCE-1 Date | Datopotamab Deruxtecan-Dlnk

Datroway

Datroway is an antibody-drug conjugate for adults with advanced non-small cell lung cancer that has an EGFR mutation and progressed after standard treatment. It delivers targeted chemotherapy directly to cancer cells to control tumor growth.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Datopotamab Deruxtecan-Dlnk
Innovator :

DAIICHI SANKYO INC
Approval Date :

17-Jan-25
Data Exclusivity Expiry :

17-Jan-29
Market Exclusivity Expiry :

17-Jan-37
Dosage Form :

Intravenous Injection
Strength :

100MG
Therapeutic Category :

Anticancer
Revenue ($M) :

9

Year-wise Projected Sales ($M) :

2025 :

183
2026 :

644
2027 :

1,461
2028 :

2,210
2029 :

3,035
2030 :

3,772
2031 :

4,507

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Datroway

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?